BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12160363)

  • 21. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood.
    Yoshimi A; van den Heuvel-Eibrink MM; Baumann I; Schwarz S; Simonitsch-Klupp I; de Paepe P; Campr V; Kerndrup GB; O'Sullivan M; Devito R; Leguit R; Hernandez M; Dworzak M; de Moerloose B; Stary J; Hasle H; Smith OP; Zecca M; Catala A; Schmugge M; Locatelli F; Führer M; Fischer A; Guderle A; Nöllke P; Strahm B; Niemeyer CM
    Haematologica; 2014 Apr; 99(4):656-63. PubMed ID: 24162791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
    Sloand EM; Wu CO; Greenberg P; Young N; Barrett J
    J Clin Oncol; 2008 May; 26(15):2505-11. PubMed ID: 18413642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
    Saunthararajah Y; Nakamura R; Wesley R; Wang QJ; Barrett AJ
    Blood; 2003 Oct; 102(8):3025-7. PubMed ID: 12829603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and treatment of acquired aplastic anaemia in adults: 142 cases from a multicentre, prospective cohort study in Shanghai, China.
    Wang W; Wang X; Xu X; Lin G
    J Int Med Res; 2011; 39(5):1994-2005. PubMed ID: 22118004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
    Lee KH; Choi SJ; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Yun SC; Joo YD; Lee WS; Kang MJ; Kim H; Park JH; Bae SH; Ryoo HM; Kim MK; Hyun MS
    Am J Hematol; 2011 May; 86(5):399-405. PubMed ID: 21523798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.
    Komrokji RS; Mailloux AW; Chen DT; Sekeres MA; Paquette R; Fulp WJ; Sugimori C; Paleveda-Pena J; Maciejewski JP; List AF; Epling-Burnette PK
    Haematologica; 2014 Jul; 99(7):1176-83. PubMed ID: 24488560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
    Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.
    Arber C; Buser A; Heim D; Gratwohl A; Tichelli A; Passweg JR
    Eur J Haematol; 2006 Mar; 76(3):255-7. PubMed ID: 16451398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppressive therapy for patients with refractory anemia.
    Asano Y; Maeda M; Uchida N; Yokoyama T; Osaki K; Shimoda K; Gondo H; Okamura T; Okamura S; Niho Y
    Ann Hematol; 2001 Nov; 80(11):634-8. PubMed ID: 11757721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.
    Deeg HJ; Jiang PY; Holmberg LA; Scott B; Petersdorf EW; Appelbaum FR
    Leuk Res; 2004 Nov; 28(11):1177-80. PubMed ID: 15380342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
    Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
    Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.
    Scott BL; Ramakrishnan A; Fosdal M; Storer B; Becker P; Petersdorf S; Deeg HJ
    Br J Haematol; 2010 Jun; 149(5):706-10. PubMed ID: 20331464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Bowen DT
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine.
    Hama A; Takahashi Y; Muramatsu H; Ito M; Narita A; Kosaka Y; Tsuchida M; Kobayashi R; Ito E; Yabe H; Ohga S; Ohara A; Kojima S
    Haematologica; 2015 Nov; 100(11):1426-33. PubMed ID: 26273061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for achieving transfusion independence in myelodysplastic syndromes.
    Thomas ML
    Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study.
    Atta EH; Dias DS; Marra VL; de Azevedo AM
    Ann Hematol; 2010 Sep; 89(9):851-9. PubMed ID: 20373101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.